Media coverage about Allergan (NYSE:AGN) has been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allergan earned a news impact score of 0.20 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.1481943639805 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Should You Follow Seth Klarman and David Tepper Into Allergan? (finance.yahoo.com)
- New report shines light on disconnect between patient and physicians when it comes to the seriousness of IBS, leading to slow diagnosis (markets.businessinsider.com)
- Allergan plc (NYSE:AGN) – Stock’s Liquidity in Focus – Nasdaq Journal (nasdaqjournal.com)
- Allergan (AGN) Given New $215.00 Price Target at Bank of America (americanbankingnews.com)
- Credit Suisse Group Increases Allergan (AGN) Price Target to $215.00 (americanbankingnews.com)
Allergan (NYSE AGN) traded down $1.28 during trading on Wednesday, reaching $159.31. 2,687,382 shares of the company were exchanged, compared to its average volume of 3,270,000. The company has a market capitalization of $53,050.00, a P/E ratio of -13.29, a P/E/G ratio of 1.16 and a beta of 1.19. Allergan has a 1-year low of $156.00 and a 1-year high of $256.80. The company has a current ratio of 2.04, a quick ratio of 1.88 and a debt-to-equity ratio of 0.41.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.81%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is -23.35%.
AGN has been the topic of several analyst reports. Royal Bank of Canada set a $250.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Sunday, October 29th. They noted that the move was a valuation call. Cantor Fitzgerald set a $231.00 target price on shares of Allergan and gave the stock a “hold” rating in a report on Wednesday, November 1st. Wells Fargo & Co reiterated an “outperform” rating and issued a $245.00 target price (down from $258.00) on shares of Allergan in a report on Thursday, November 2nd. Morgan Stanley cut their target price on shares of Allergan from $228.00 to $200.00 and set an “equal weight” rating on the stock in a report on Thursday, November 2nd. Finally, Leerink Swann reiterated an “outperform” rating and issued a $237.00 target price on shares of Allergan in a report on Monday, November 27th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $227.23.
In other Allergan news, Director Christopher J. Coughlin bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The stock was acquired at an average price of $163.30 per share, with a total value of $1,633,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William Meury sold 11,807 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is owned by insiders.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.